Cover Story
Clinical
Proven curative regimens containing platinum-based drugs—cisplatin and carboplatin—have become largely unavailable because of a nationwide drug shortage. The institutions that have some supplies of cisplatin and carboplatin are setting up algorithms for rationing their dwindling stocks, which usually means giving top priority to patients treated with curative intent and denying standard-of-care treatment to patients who cannot be cured but who can still benefit from these drugs.
In Brief
Clinical Roundup
Drugs & Targets
Trending Stories
- Moving from mandate to mission: Community outreach and engagement at NCI-designated cancer centers
“COE is broken.” - Don’t confirm RFK Jr. for HHS, 77 Nobel laureates urge the Senate
- Art exhibit at University of Miami Sylvester bridges North and South America
- VCU awarded $9M from NCI to establish Cancer Control Equity Research Center
- The Cancer Letter’s most-read stories of 2024
- The Human Tumor Atlas Network charts the roadmap for advancing spatial omics